Glaxo Files Cancer Drug For Approval With FDA

by Jyothsna on  February 28, 2007 at 12:02 PM Drug News   - G J E 4
Glaxo Files Cancer Drug For Approval With FDA
Tykerb, a breast cancer drug from Glaxo Smithkline has been filed for approval with America's FDA and European regulators. The result of this approval will be known by March 13 and by September in US and Europe respectively.

According to the company sources, this drug is expected to generate Ģ 1 bn a year not only from treating breast cancer but also from brain and kidney carcinomas. Navid Malik, an analyst from Collins Stewart states that Tykerb will be similar to Avastin, a Roche drug intended for colorectal, lung or breast cancer.

Advanced trial for Tykerb on its efficacy against neck and head tumors will commence soon. Jean-Pierre Garnier who heads Glaxo Smithkline said that the drug will be given to people who have just had surgery as part of phase III trial to prevent the tumor from growing in size. As per the report on Phase I study presented recently at Barcelona, 89% patients responded positively to Tykerb taken in combination with chemotherapy and radiation.

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions
iam youssef nazer graduated as pharmacist and working in solvay pharmaceuticals in lebanon, until now for more than 10 years wish to apply as managerial position best regards
guest Friday, April 13, 2007
invest in glaxo smithkline
guest Friday, March 9, 2007

You May Also Like